Stay updated on Biomarker-Directed Therapy in mCRC Clinical Trial
Sign up to get notified when there's something new on the Biomarker-Directed Therapy in mCRC Clinical Trial page.

Latest updates to the Biomarker-Directed Therapy in mCRC Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.5%
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check48 days agoChange DetectedThe page has been updated to include new drug names related to colorectal cancer treatment, specifically Atezolizumab, Vemurafenib, Bevacizumab, Trastuzumab, Pertuzumab, Cobimetinib, 5-FU/LV, and Capecitabine, while significant details about a clinical trial have been removed.SummaryDifference23%
- Check55 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check62 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check91 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
Stay in the know with updates to Biomarker-Directed Therapy in mCRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker-Directed Therapy in mCRC Clinical Trial page.